#### Pre-Diagnosis Observational and Prescription History associated with Alzheimer's Disease Incidence

#### Gareth Williams

Wolfson Sensory Pain and Regeneration Centre, King's College London, SE1 UL, email: gareth.2.williams@kcl.ac.uk

#### Abstract

**Background:** Alzheimer's disease (AD) has so far proved refractory to intervention. However, disease incidence is variable across prior medication and observational measures. The present study adopted a data-driven approach to inform possible drug repurposing strategies in the light of concurrent prescription and biometric data.

**Methods and Results:** A real-world dataset was harnessed to compare observational and prescription data for 250,000 individuals prior to AD diagnosis against an age-, sex-, and clinical practice-matched control cohort with no AD history. Observation data was shown to both explain the associations of classes of drug prescription with AD incidence and to bolster the repurposing potential of the GLP-1 agonist class of anti-diabetic drugs.

**Conclusion:** This study provides insights into how drug repurposing based on prescription histories can be informed by concurrent observational data. These findings offer novel insights to be explored in future research on causal models for AD progression.

#### Introduction

With the exception of the controversial approval for AD of the at best moderately effective antiamyloid antibody therapies [1-4], with aducanumab being recently discontinued due to cost and side effect issues[5], there have been no new AD therapeutics coming to market in over 20 years. The inherently complex nature of the disease with multiple pathological features associated with various biological pathways and risk factors encompassing lifestyle[6] and genetic variants[7] has led researchers to go so far as to question AD's status as a disease and argue that it should be rather considered a syndrome<sup>[8]</sup> due to the mismatch in causal factors and ultimate presentation. Turning away from target-based drug discovery approaches, the wealth of data on the disease has informed lifestyle modifications[9, 10] and motivated a search for repurposing candidates where existing approved therapeutics with extensive safety data and prescription histories are hypothesised as candidate therapeutics for diseases for which they weren't initially developed[11, 12]. Other neurodegenerative conditions like Parkinson's disease (PD) have also been the subject of repurposing efforts[13]. Repurposing can take many forms from the emergence of targets shared with other diseases[14] to the correlation of high content biological data, such as gene expression profiles[15, 16], between disease and compound. A more direct approach is based on epidemiology, where low disease incidence associations with drug prescription may inform a new intervention route, as shown with the emergence of salbutamol as a potential protective against PD though an analysis of the Norwegian NorPD prescription database [17]. However, without a viable biological mechanism, epidemiology-based associations do not establish causality but rather inform future research through generating hypotheses.

The COVID pandemic precipitated the Health Data Research UK (HDRUK), through the British Heart Foundation Data Science Centre, making available primary health care data for 57 million people in England to researchers in the hope of gaining insights into amelioration strategies[18]. The HDRUK data is currently available for COVID pandemic related studies, at least on a fee free basis. However, NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. on a smaller scale, the well-established Clinical Practice Research Datalink (CPRD)[19, 20] provides curated data on approximately 19 million currently contributing (67 million historical) patient's observation and prescription histories from across the UK. CPRD provides an ideal platform to investigate associations between disease incidence and prior prescription history and observational data and has been the basis of investigating associations of dementia with inflammatory biomarkers[21], comorbidities like type 2 diabetes (T2D) [22] and drug use[23, 24]. Other initiatives like the UK Biobank[25] provide the researcher with valuable diagnostic data linked to genetic variant information and tissue samples for over half a million individuals.

In the present work we sought to harness electronic health records from a large real-world dataset to investigate the associations, both positive and negative, between AD incidence and prior prescription history and observational data. Specifically, we collected a cohort with an AD diagnosis and defined the index date as the date of first diagnosis. Everyone with an AD diagnosis was matched with people of the same age, sex and clinical practice with no AD diagnosis at index. This effectively constituted a retrospective case-control study to investigate disease risk factors prior to onset. We found that high systolic blood pressure (SBP) and low blood albumin levels are significantly associated with a higher incidence of AD up to ten years prior to diagnosis. A combination of blood-borne biomarkers and biometric data gathered 10 to 20 years prior to diagnosis of AD facilitated a modest predictability of future AD incidence with an operating characteristic (ROC) area under the curve (AUC) of 0.79+/-0.001. An analysis of prescription histories revealed both positive and negative associations of drug prescription with AD incidence. An analysis of concurrent observational data was used to investigate the possible causal relationships between drug use and AD incidence. Notably, the negative association of anti-hypertensives with AD incidence was explained by SBP being higher in the cohort going on to develop AD. The highly significant negative association of the migraine triptan medications was shown to be confounded by both SBP levels and migraine incidence. Two classes of T2D medications were shown to be associated with a lower AD incidence and this bolstered by the observation of a higher AD incidence in the T2D sub cohort. Our analysis within the female cohort recapitulates the reported AD risk lowering potential of hormonal therapies. It is hoped that this analysis will help build hypotheses around new repurposing candidates and lend support to existing AD therapy candidates in trials.

## Methods

# Cohort

The present study used routinely collected data from the CPRD, one of the world largest primary care electronic health records datasets. The CPRD contains medical records for about 24% of the UK primary care population with complete prescribing data and clinical diagnosis information, laboratory tests, and referrals made following a primary care consultation. The CPRD population is representative in terms of size, patients' socio-demographic attributes, and geographical distribution of practices. The data have been validated extensively for pharmaco-epidemiological, clinical and public health investigations. The study population included patients aged 50 years or over at the time of a first diagnosis of AD between 1<sup>st</sup> January 2012 and 31<sup>st</sup> December 2022. These patients were individually matched on age, sex and practice with a set of controls without AD, see Table 1. There were on average six controls per AD individual. AD diagnosis was defined using SNOMED CT and Read medical codes reflective of an AD event (see Supplementary Table S1 for a complete list of codes). Data was extracted from the CPRD Aurum version in September 2023.

Table 1. The case-control cohort characteristics for AD.

	WOMEN		MEN	
	AGE(mean+/-sd)	Ν	AGE(mean+/-sd)	Ν
AD	83.22+/-7.96	157195	80.88+/-8.11	103709
CTL	83.22+/-7.97	931257	80.88+/-8.10	616870

## Observations

Individuals were assigned to T2D and migraine status based on observations corresponding to the SNOMED CT codes in Supplementary Tables S2 and S3. The observational biometric and blood borne variables defined for the cohort are listed in Supplementary Table S4. Each measure has a mean and standard deviation and measures outside 2 standard deviations of the mean were dropped as erroneous or outliers. The measures have various coverage over the cohorts, see Supplementary Table S4.

# Medication

Medication incidence is determined by prescription events for any of the British National Formulary (BNF) (<u>www-medicinescomplete-com.apollo.worc.ac.uk/#/browse/bnf</u>) (1364) medications, all prescription variants of a given BNF type are pooled. Two different time ranges prior to index were analysed, pooling prescription data 5 to 10 and 10 to 20 years prior diagnosis. To address the differential coverage of prescription data the cohort matching was refined so that the overall medication frequency or observation frequency over the given age range prior to index period was non-zero and within 20% for AD and non-AD pairing. The cohort characteristics 5 to 10 and 10 to 20 years prior to index are shown in Table 2.

Tabel 2 The cohort summary for the medication association with AD incidence analysis. Cases were matched with controls based on age, sex, clinical practice together with the number of observations and prescriptions over the given time period.

	0 years prior AD WOMEN		MEN	
	AGE(mean+/-sd)	N	AGE(mean+/-sd)	N
AD	83.10+/-8.04	55537	80.52+/-8.29	29646
CTL	83.05+/-8.07	70222	80.46+/-8.33	35352
		, or the	00.10.1 0.00	
	20 years prior AD WOMEN	, other	MEN	
	20 years prior AD	N		N
	20 years prior AD WOMEN		MEN	

## Associations

The associations between the biometric and blood borne measures and AD status were defined as Cohen's effect sizes. For the prediction model, the data was split into 70:30 training and validation sets, and a random forest model based on 15 measures plus age and sex, selected based on a cohort coverage of at least half of those with blood pressure readings, was built and fit to the training data. The model was then tested on the validation set. The random forest analysis was carried out within the R environment using the randomForest package[26]. Predictability was assessed through a ROC AUC analysis.

The associations of drug prescriptions with AD incidence were defined by the corresponding odds ratios, where drug prescription status was a binary call based on any prescription of the drug over the given time period. For drugs mostly prescribed for one sex, based on prescription frequency being above 10-fold higher in men versus women or women versus men, analysis was restricted to the given sex. To test for the robustness of cohort matching we also calculated odds ratios with age, sex and number of observations as covariates with a linear logistic regression model. As a further sensitivity

analysis, we included clinical practice as a random effect in the logistic regression model, we found that the inclusion of this error term and additional covariates had no significant effect on our conclusions.

#### Results

### **Biometric associations with AD incidence**

Certain biometrics, like hypertension[27-29] and BMI[6], and blood borne marker levels[30-33] are associated with increased risk of developing AD with differences between people going on to develop AD and those that aren't sometimes arising a relatively long time prior to diagnosis. As can be seen in Table 3 SBP is significantly high in the AD cohort 10 years prior to diagnosis, with an effect size of 0.89. Here, we find SBP in the AD cohort of 140.78+/-11.80 compared to 128.38+/-14.87 in the controls. Where we defined the AD cohort to mean those who will go on to develop the disease within the time frame of our dataset. The positive association of high SBP is consistent from ten years prior to diagnosis whereas the positive association of diastolic blood pressure (DBP) is more marked at ten years prior diagnosis than at later stages, with an effect size of 0.36 10 to 20 years prior index dropping to 0.05 in the 5 to 10 years range. Another previously reported association with AD incidence is blood serum albumin level[34]. This observation is validated in our dataset with albumin levels being the strongest negative association with AD incidence across the ten years prior to diagnosis, with levels of 41.97+/-2.80 in the AD cohort and 42.82+/-3.04 in the controls. This association becomes stronger as diagnosis gets closer going from an effect of -0.27 at 10 to 20 years and -0.34 at 5 to 10 years prior to index.

Table 3. Most significant associations measured by Cohen's d effect size with confidence intervals for blood measures and biometrics with AD for data averaged over 10 to 20 and 5 to 10 years prior to diagnosis.

	10 to 20 years prio	r AD			5 to 10 years prior	AD		
MEASURE	Effect	z	Controls	Cases	Effect	Z	Controls	Cases
Systolic arterial pressure	0.89 (0.88 0.89)	380.74	532574	206250	0.78 (0.78 0.79)	377.44	702844	232436
Diastolic arterial pressure	0.36 (0.35 0.36)	154.35	532574	206250	0.05 (0.04 0.05)	22.82	702844	232436
Serum urea level	0.53 (0.52 0.54)	146.27	199142	126440	0.62 (0.61 0.62)	210.44	379119	185311
Serum creatinine level	0.37 (0.37 0.38)	115.15	260245	159511	0.45 (0.45 0.46)	160.94	431660	206344
Serum albumin level	-0.27 (-0.28 -0.27)	-82.33	227793	141770	-0.34 (-0.34 -0.33)	-124.69	400235	196314
BMI	0.18 (0.18 0.19)	64.61	385426	158549	0.07 (0.07 0.08)	26.21	458876	162233
Plasma glucose level	0.24 (0.23 0.25)	52.34	123529	80656	0.25 (0.24 0.26)	67.88	225115	120762
Serum ferritin level	0.37 (0.36 0.39)	46.07	44579	25685	0.31 (0.30 0.32)	61.58	121789	66178
Serum testosterone level	0.94 (0.90 0.99)	45.77	10188	2709	0.92 (0.88 0.96)	50.62	19029	3068
Serum alkaline phosphatase level	0.16 (0.15 0.16)	45.42	222549	138334	0.17 (0.17 0.18)	61.54	381972	188020
Neutrophil count	-0.12 (-0.13 -0.12)	-40.68	275019	143771	0.02 (0.01 0.02)	7.51	462694	202926
Platelet count	-0.13 (-0.13 -0.12)	-39.57	287296	148334	-0.15 (-0.15 -0.14)	-54.01	462701	202390
Plasma urea level	0.53 (0.51 0.56)	38.38	12753	8976	0.55 (0.53 0.57)	47.21	21237	12034
Total white cell count	-0.12 (-0.12 -0.11)	-38.23	285247	147181	-0.03 (-0.03 -0.02)	-11.4	464363	202847
Serum glucose level	0.31 (0.29 0.32)	35.98	34341	24297	0.30 (0.29 0.32)	42.33	56417	32344
ALT/SGPT serum level	-0.12 (-0.13 -0.11)	-32.76	163690	109470	-0.24 (-0.25 -0.24)	-76.04	236624	130858
Plasma fasting glucose level	0.18 (0.17 0.19)	30.66	67846	51291	0.17 (0.16 0.18)	40.53	153285	86210
Plasma creatinine level	0.40 (0.37 0.42)	29.71	14514	9566	0.43 (0.41 0.45)	40.46	26926	14196
Monocyte count	0.08 (0.08 0.09)	26.55	273303	142968	0.20 (0.20 0.21)	75.9	462225	202827
Serum thyroid stimulating hormone level	0.10 (0.09 0.11)	24.96	183629	105520	0.09 (0.08 0.09)	29.35	367896	172837

Given that there are multiple factors showing association with AD incidence we sought to build a predictive model based on these factors. As can be seen in Table 3, there is variable coverage of the cohort across the measures. Restricting measures defined in the 10 to 20 years prior to index with cohort coverage above half of the SBP we are left with 15 measures defined for a cohort of 219,639. Splitting this data into 70:30 training and validation sets and training a random forest predictor model on the training set we find a ROC AUC (mean+/-sd) of 0.79+/-0.001 from 10 independent data split

runs (accuracy 0.71+/-0.001, precision 0.78+/-0.002, recall 0.66+/-0.003). Not surprisingly, this modest level of predictability falls far short of models based on AD specific biomarkers such as phosphorylated tau and amyloid[35]. However, in the next section we will see how the observational correlates of AD incidence can help in the interpretation of epidemiological drug repurposing.

#### Medication prescription associations with AD incidence

As described in the Methods section, the study cohort was filtered based on matching prescription and observation frequencies over given time frames prior to index date. To see to what extent prior drug use is associated with AD incidence we gathered prescription data in time frames of 5 to 10 and 10 to 20 years prior to diagnosis. For sex specific drugs analysis was restricted to the given sex. The top positive and negative associations of drug prescriptions prior to index with AD incidence are shown in Table 4.

Table 4. The associations of prior drug prescriptions with AD incidence. The top 20 positive and negative associations are shown (ranked by Z score) for drugs taken by both sexes.

	5-10 years		10-20 years			5-10 years		10-20 years	
DRUG	logODDs	Z	logODDs	Z	DRUG	logODDs	Z	logODDs	Z
PHENOXYMETHYLPENICILLIN	-0.85 (-0.89 -0.81)	-43.3	-0.72 (-0.76 -0.69)	-44.03	ASPIRIN	1.00 (0.98 1.03)	86.42	1.09 (1.07 1.12)	76.1
CLINDAMYCIN	-1.40 (-1.51 -1.30)	-26.6	-1.46 (-1.58 -1.35)	-24.75	SIMVASTATIN	0.86 (0.83 0.88)	77.9	0.93 (0.91 0.96)	62.3
ORLISTAT	-1.23 (-1.33 -1.14)	-25.1	-0.75 (-0.85 -0.65)	-15.25	PARACETAMOL	0.77 (0.75 0.79)	75.99	0.55 (0.53 0.57)	50.18
NICOTINE	-0.71 (-0.77 -0.65)	-23.9	-0.35 (-0.40 -0.29)	-12.2	BENDROFLUMETHIAZIDE	0.84 (0.81 0.86)	64.47	0.94 (0.91 0.97)	66.36
FLUOXETINE	-0.58 (-0.63 -0.53)	-23.8	-0.46 (-0.51 -0.42)	-20.45	CALCIUM CARBONATE	0.90 (0.87 0.93)	62.16	0.86 (0.82 0.90)	40.52
SUMATRIPTAN	-1.21 (-1.32 -1.11)	-22.1	-0.72 (-0.83 -0.61)	-13.12	COLECALCIFEROL	0.88 (0.85 0.91)	59.46	0.97 (0.92 1.02)	39.48
FLUCONAZOLE	-0.61 (-0.67 -0.56)	-21.7	-0.54 (-0.60 -0.49)	-18.5	AMLODIPINE	0.80 (0.77 0.82)	58.14	0.87 (0.83 0.91)	44.87
LYMECYCLINE	-1.24 (-1.37 -1.12)	-20	-1.11 (-1.29 -0.95)	-12.86	FUROSEMIDE	0.90 (0.86 0.93)	51.37	0.85 (0.81 0.89)	38.51
VARENICLINE	-1.01 (-1.11 -0.91)	-19.7	-0.82 (-0.98 -0.66)	-10.07	HYPROMELLOSE	1.02 (0.98 1.06)	49.43	1.15 (1.10 1.20)	45.59
SALBUTAMOL	-0.23 (-0.26 -0.21)	-18.7	-0.28 (-0.31 -0.25)	-20.01	PARAFFIN	0.54 (0.52 0.57)	47.25	0.35 (0.32 0.38)	25.73
MEBENDAZOLE	-1.54 (-1.71 -1.37)	-17.7	-1.62 (-1.76 -1.48)	-22.3	ATORVASTATIN	0.66 (0.63 0.69)	44.57	0.83 (0.79 0.87)	39.76
ERYTHROMYCIN	-0.26 (-0.29 -0.23)	-16.4	-0.22 (-0.24 -0.19)	-16.03	ATENOLOL	0.69 (0.66 0.72)	42.78	0.81 (0.78 0.84)	51.31
FOLIC ACID	-0.41 (-0.45 -0.36)	-16.3	-1.02 (-1.08 -0.95)	-30.91	MACROGOL	0.67 (0.64 0.70)	42.52	0.50 (0.44 0.55)	18.17
METRONIDAZOLE	-0.30 (-0.34 -0.26)	-15.3	-0.22 (-0.26 -0.18)	-11.3	IBUPROFEN	0.47 (0.45 0.49)	42.29	0.50 (0.48 0.52)	44.83
PRILOCAINE	-1.57 (-1.79 -1.37)	-14.8	-1.48 (-1.71 -1.27)	-13.33	CO CODAMOL	0.45 (0.43 0.47)	41.96	0.53 (0.50 0.55)	43.4
CLOTRIMAZOLE	-0.21 (-0.24 -0.18)	-14.6	-0.21 (-0.24 -0.19)	-14.68	OMEPRAZOLE	0.45 (0.42 0.47)	40.49	0.55 (0.52 0.58)	36.76
CYPROTERONE	-1.57 (-1.79 -1.36)	-14.4	-2.53 (-2.78 -2.30)	-20.94	RAMIPRIL	0.57 (0.54 0.59)	40.34	0.72 (0.68 0.76)	35.71
PROGUANIL	-0.59 (-0.68 -0.50)	-12.9	-0.13 (-0.22 -0.05)	-3.1	QUININE	0.95 (0.91 1.00)	39.97	1.08 (1.02 1.13)	38.76
ATOVAQUONE	-0.59 (-0.68 -0.50)	-12.6	-0.14 (-0.23 -0.05)	-2.95	BISOPROLOL	0.76 (0.72 0.80)	39.76	0.84 (0.77 0.90)	24.8
HYOSCINE BUTYLBROMIDE	-0.38 (-0.44 -0.32)	-12.6	-0.10 (-0.18 -0.03)	-2.73	LACTULOSE	0.64 (0.61 0.68)	39.15	0.40 (0.37 0.44)	21.89

Table 5. The associations of prior drug prescriptions with AD incidence. The top 20 positive and negative associations are shown (ranked by Z score) for drugs taken predominantly by women.

	5-10 years		10-20 years			5-10 years		10-20 years	
DRUG	logODDs	Ζ	logODDs	Z	DRUG	logODDs	Ζ	logODDs	Z
ESTRADIOL	-1.38 (-1.43 -1.34)	-62.7	-1.03 (-1.06 -0.99)	-57.34	ESTRIOL	0.54 (0.48 0.61)	16.46	0.83 (0.76 0.90)	23.54
NORETHISTERONE	-2.34 (-2.43 -2.25)	-49.5	-1.24 (-1.29 -1.19)	-48.99	STRONTIUM	1.17 (1.00 1.34)	13.26	0.97 (0.69 1.27)	6.62
LEVONORGESTREL	-4.75 (-5.03 -4.49)	-35.1	-3.93 (-4.09 -3.78)	-48.82	IBANDRONIC	1.01 (0.85 1.18)	11.89	1.14 (0.85 1.45)	7.52
PROGESTERONE	-2.02 (-2.14 -1.90)	-31.8	-0.78 (-0.85 -0.71)	-22.7	ANASTROZOLE	0.54 (0.40 0.67)	7.81	0.49 (0.29 0.70)	4.72
MEDROXYPROGESTERONE	-1.98 (-2.11 -1.86)	-31.1	-0.74 (-0.80 -0.67)	-21.1	RALOXIFENE	0.95 (0.69 1.21)	7.19	0.97 (0.76 1.19)	8.85
MEFENAMIC	-2.87 (-3.07 -2.68)	-28.6	-1.98 (-2.09 -1.87)	-35.53	TAMOXIFEN	0.38 (0.26 0.50)	6.33	0.81 (0.70 0.92)	14.5
ETHINYLESTRADIOL	-5.86 (-6.33 -5.46)	-26.8	-4.26 (-4.44 -4.10)	-49.3	LETROZOLE	0.53 (0.35 0.71)	5.74	0.75 (0.35 1.17)	3.58
TRANEXAMIC	-2.97 (-3.20 -2.76)	-26.6	-2.12 (-2.27 -1.99)	-29.33	DENOSUMAB	0.90 (0.47 1.34)	4.05	0.21 (-3.02 3.44)	0.15
DESOGESTREL	-5.03 (-5.43 -4.67)	-26.1	-4.12 (-4.45 -3.83)	-25.9	ALENDRONIC	2.72 (1.10 5.62)	2.61	NA	NA
ETONOGESTREL	-5.63 (-7.02 -4.67)	-9.81	-4.08 (-5.11 -3.31)	-9.06	EXEMESTANE	0.35 (0.05 0.65)	2.3	0.52 (-0.07 1.13)	1.72
TIBOLONE	-0.54 (-0.69 -0.39)	-6.89	0.40 (0.30 0.49)	8.47					
EFLORNITHINE	-1.06 (-1.38 -0.75)	-6.55	-0.57 (-1.02 -0.14)	-2.54					
CO CYPRINDIOL	-5.52 (-8.38 -4.03)	-5.54	-4.92 (-7.79 -3.43)	-4.99					
OESTROGENS	-0.23 (-0.32 -0.14)	-4.84	0.41 (0.35 0.46)	14.02					
BROMOCRIPTINE	-3.53 (-6.40 -2.01)	-3.5	NA	NA					
NONOXINOL	-1.65 (-2.73 -0.80)	-3.45	-2.18 (-2.65 -1.76)	-9.55					
MEPACRINE	-2.07 (-4.98 -0.42)	-1.97	0.21 (-1.48 1.89)	0.25					
ZANAMIVIR	-1.96 (-4.88 -0.29)	-1.88	NA	NA					
DIAZOXIDE	-0.46 (-3.53 1.89)	-0.37	NA	NA					
ESLICARBAZEPINE	-0.46 (-3.53 1.89)	-0.37	NA	NA					

Table 6. The associations of prior drug prescriptions with AD incidence. The top 20 positive and negative associations are shown (ranked by Z score) for drugs taken predominantly by men.

	5-10 years		10-20 years	
DRUG	logODDs	Z	logODDs	Z
TAMSULOSIN	1.04 (0.98 1.09)	35.7	1.13 (1.04 1.22)	25.08
FINASTERIDE	1.05 (0.96 1.13)	24.01	1.20 (1.06 1.34)	17.11
DUTASTERIDE	1.14 (0.97 1.31)	12.95	1.16 (0.87 1.46)	7.64
ALFUZOSIN	0.84 (0.70 0.98)	11.97	0.92 (0.75 1.08)	10.9
LEUPRORELIN	1.43 (1.13 1.75)	9.11	NA	NA
BICALUTAMIDE	0.99 (0.78 1.22)	8.87	1.03 (0.69 1.39)	5.8
INDORAMIN	1.18 (0.89 1.49)	7.77	1.11 (0.89 1.34)	9.81
SILDENAFIL	0.21 (0.14 0.27)	6.54	0.62 (0.54 0.69)	16.48
TADALAFIL	0.21 (0.13 0.30)	4.91	0.66 (0.54 0.78)	10.78
TRIPTORELIN	1.16 (0.63 1.73)	4.19	NA	NA
VARDENAFIL	0.30 (0.14 0.45)	3.65	0.51 (0.30 0.71)	4.8

In agreement with our observations on the AD risk associated with high blood pressure, we find enhanced prescriptions for anti-hypertensive medications (bendroflumethiazide, amlodipine, furosemide, atenolol, bisoprolol, ramipril) in the AD cohort, see Table 4 on the right. Of interest in the negative association drug set is Salbutamol which has previously been reported to protect against PD based on epidemiological evidence[17], but this has been disputed based on confounding effects of smoking and the protective effects of nicotine[36]. Interestingly, salbutamol has been hypothesised as a PD repurposing candidate based its driving the transcription of the FGF20[13]. Smoking has been reported to be associated with increased rates of dementia[37, 38], ranking number three in the set of modifiable risks[39]. However, there have been reports on the possible cognitive benefits of nicotine[40, 41]. In this context, the present analysis shows a negative association of nicotine with AD incidence, and it would be interesting to include data on non-prescription nicotine use to see to what extent the effects of salbutamol and nicotine can be separated.

## Type 2 diabetes drugs

Not shown in Table 4 are the GLP-1 agonist and SGLT2 inhibitor class of T2D medications which have consistent negative associations with AD incidence, see Table 7 for details. Given the consistent negative association we also defined correlations for prescription of any of the GLP-1 drugs in the data base, see entries under pooled in Table 7. Interestingly, the GLP-1 agonist liraglutide has been recently reported to have positive effects in a year-long phase 2 trial in people with AD[42] and the closely related exenatide has shown evidence of reducing AD risk[43]. Other groups have reported on the positive effects of GLP-1 agonists in PD. This result is of interest outside diabetes as a GLP-1 medication, semaglutide, has recently been licensed as a weight loss drug[44, 45]. It will be of great interest to follow dementia incidence in this population. Another class of T2D medication showing potentially positive effects are the glucose lowering SGLT2 inhibitors, see Table 7. This has also been reported in a recent systematic review [46]. The SGLT2 inhibitors have only been licenced relatively recently and we thus did not have data to power an analysis 10 years prior to diagnosis of AD. These results are of especial interest as T2D is a known risk factor for developing the disease[22, 47-49]. In agreement with this, our data show a positive association with the most frequent T2D medication, metformin, and AD incidence, (logODDs 0.37 (0.31 0.42) Z 12.51 at 10 to 20 years prior AD incidence and logODDs 0.20 (0.17 0.24) Z 10.64 at 5 to 10 prior AD incidence). The observational data enables us to uncouple the effects of disease and the drugs for which they are prescribed. To this end we delimited T2D disease cohorts within the 10 to 20 years prior AD diagnosis medication dataset (6,382 men aged 80.57+/-7.77 and 11,859 women aged 82.69+/-7.70). In agreement with T2D being a risk factor for AD, we find a higher future AD incidence in those with a T2D observation, within this time frame, of 48% as opposed to 45% in those with no T2D observation, with an effect size of 0.13 (0.10 0.16) and Z score 8.15. This observation bolsters the positive effects of the T2D drugs as they show a negative association with AD and are prescribed for a condition that is associated with a higher AD risk. Further, restricting the analysis to the T2D cohort we find a stronger negative association with AD incidence with the GLP-1 medication, with an effect size of -1.34 (-2.25 -0.57) and Z score of -3.19, contrast with Table 7.

# **Triptans and migraine**

Various triptan migraine medications appear to negatively associate with AD incidence. The correlations for the complete set of triptan drugs are shown in Table 7 together with the correlations for a prescription of any of the triptans. In contrast to T2D discussed above, there is no consensus in the literature as to whether migraine is a risk factor for AD, with groups reporting contradictory results [50, 51]. Interestingly, there may be an association of blood pressure with migraine incidence, with a large study showing a positive association of low blood pressure and migraine incidence in adolescents[52]. However, there does not appear to be a consensus on whether migraine is due to high or low blood pressure or whether there is indeed any association[53]. In this context, our data shows that those on the triptan class of migraine medication have significantly lower SBP. For, example at 10 to 20 years prior to AD diagnosis SBP is lower in the triptan cohort in both the control and case cohorts, with effect sizes of -0.24 (-0.29 -0.20) N triptans +/- 1967/65027 in the controls and -0.23 (-0.30 -0.16) N triptans +/- 794/62149 in cases. Triptans make up only for part of the migraine prescription options, with NSAIDs being another option, see the BNF drug data (WWWmedicinescomplete-com.apollo.worc.ac.uk/#/browse/bnf). The observational data allows for delimiting a migraine cohort within the AD case control cohort. The overall migraine incidence 10 to 20 years prior to index is 3.4%. However, we find that this rate is significantly lower, 2.06%, in the those going on to develop AD, with an effect size of -0.83 (-0.88 -0.77) and Z score of -27.73. Restricting to the migraine cohort, we now have no negative association of triptan medication with AD status, with 31% of the migraine cohort having triptan medication in both the AD and control cohorts. Thus, we can conclude that in this instance the negative association we found in our initial analysis was driven by the underlying disease status as opposed to the medication for the disease. With regard to establishing a rigorous association between migraine, AD and SBP, a further appropriately matched case control analysis would have to be carried out.

# Hormonal drugs

In the analysis of drugs predominantly prescribed to women, see Table 5, we find consistent negative associations with hormonal medications with the top negative association with AD incidence at both 5 to 10 years and 10 to 20 years prior index being with the postmenopausal medication estradiol. In this context the protective effects of oestrogen in the context of AD it has been reported that postmenopausal women on oestrogen had significantly delayed AD onset[54, 55]. However, a trial in AD patients did not show a positive effect of disease progression, rather the reverse[56, 57]. It has been suggested that the positive effects of hormone replacement are only present in a younger cohort[58]. Prescription of the weaker estrogen estriol is associated with increased AD incidence, and this may be accounted for by the types of conditions it is prescribed for, such as urinary tract infections and vaginal atrophy in contrast with the hormonal replacement use of the negatively associated estrogen drugs.

The number of male specific drugs is smaller than those prescribed specifically for women, and we find no significant negative associations with AD incidence and prescription of these medications. The drugs associated with increased AD incidence are prescribed for prostate enlargement and impotence, see Table 6. It is not clear how these medications of the corresponding diseases are linked to AD,

though it has been reported that men with benign prostate hyperplasia have a higher rate of AD and other dementias[59].

Table 7. Sets of compounds belonging to classes. The associations based on prescriptions of any of the medications in the various classes are shown as combined scores.

TRIPTANS				
	5 to 10 years		10 to 20 years	
	logODDS	Z	logODDS	Z
ALMOTRIPTAN	-1.24 (-1.71 -0.80)	-5.33	-0.99 (-1.43 -0.59)	-4.68
ELETRIPTAN	-2.09 (-5.00 -0.44)	-2.02	-0.32 (-1.90 1.09)	-0.43
FROVATRIPTAN	-1.97 (-2.73 -1.34)	-5.61	-0.81 (-1.37 -0.29)	-2.93
NARATRIPTAN	-1.23 (-1.51 -0.97)	-9.07	-0.78 (-0.98 -0.60)	-8.13
RIZATRIPTAN	-1.38 (-1.61 -1.16)	-12.13	-0.82 (-1.02 -0.63)	-8.3
SUMATRIPTAN	-1.21 (-1.32 -1.11)	-22.11	-0.72 (-0.83 -0.61)	-13.1
ZOLMITRIPTAN	-1.32 (-1.55 -1.09)	-11.27	-0.70 (-0.89 -0.53)	-7.64
POOLED	-1.22 (-1.31 -1.13)	-27.53	-0.74 (-0.82 -0.66)	-17.7

SGLT2 antagonists							
	5 to 10 years						
	logODDS	z					
CANAGLIFLOZIN	-0.91 (-1.61 -0.29)	-2.75					
DAPAGLIFLOZIN	-0.63 (-1.04 -0.25)	-3.18					
EMPAGLIFLOZIN	-0.88 (-1.90 -0.01)	-1.88					

-0.70 (-1.03 -0.39)

#### HORMONALS

POOLED

GLP1 agonists					
	5 to 10 years			10 to 20 years	
	logODDS	Ζ		logODDS	Z
DULAGLUTIDE	-0.88 (-2.80 0.58)		-1.08	NA	NA
EXENATIDE	-0.54 (-0.86 -0.23)		-3.35	-0.86 (-1.73 -0.10)	-2.1
LIRAGLUTIDE	-0.61 (-0.91 -0.32)		-4.09	-1.06 (-2.32 -0.03)	-1.87
POOLED	-0.59 (-0.82 -0.37)		-5.24	-0.81 (-1.54 -0.15)	-2.3

HURMUNALS				
	5 to 10 years		10 to 20 years	
	logODDS	Z	logODDS	Z
DESOGESTREL	-5.03 (-5.43 -4.67)	-26.1	-4.12 (-4.45 -3.83)	-25.9
ESTRADIOL	-1.38 (-1.43 -1.34)	-62.7	-1.03 (-1.06 -0.99)	-57.3
ETHINYLESTRADIOL	-5.86 (-6.33 -5.46)	-26.8	-4.26 (-4.44 -4.10)	-49.3
ETONOGESTREL	-5.63 (-7.02 -4.67)	-9.81	-4.08 (-5.11 -3.31)	-9.06
LEVONORGESTREL	-4.75 (-5.03 -4.49)	-35.1	-3.93 (-4.09 -3.78)	-48.8
MEDROXYPROGESTERONE	-1.98 (-2.11 -1.86)	-31.1	-0.74 (-0.80 -0.67)	-21.1
NORETHISTERONE	-2.34 (-2.43 -2.25)	-49.5	-1.24 (-1.29 -1.19)	-49
OESTROGENS	-0.23 (-0.32 -0.14)	-4.84	0.41 (0.35 0.46)	14
PROGESTERONE	-2.02 (-2.14 -1.90)	-31.8	-0.78 (-0.85 -0.71)	-22.7
POOLED	-1.76 (-1.80 -1.72)	-90.3	-1.07 (-1.10 -1.04)	-69.6

-4.3

#### Conclusions

Effective disease modifying therapeutics for AD have so far proved elusive due to the multi-factorial nature of the condition with a complex set of diverse causes converging on catastrophic dementia with onerous and increasing burdens on the health care system as well as the obvious toll it takes on the quality of life for the individual. The increasing availability of curated diagnosis, prescription and biometric data, through resources such as the CPRD[19], HDRUK[18] and UK Biobank[25], has allowed for an investigation of the associations between modifiable lifestyle factors and disease incidence that can inform guidelines as well as providing a basis for segregating populations for focussed early intervention. Also, strong associations between drug use and disease incidence can build hypotheses for repurposing initiatives. The present study sought to investigate both biometric and prescription associations with future AD incidence within one case-control cohort, where each case is demographically matched with a control at the time of diagnosis and data collected prior to diagnosis.

Our findings recapitulate several significant associations between biometric measures and the risk of developing AD. Specifically, SBP and DBP were consistently associated with an increased risk of AD, with SBP showing a significant positive association up to ten years before diagnosis. Blood serum albumin levels also emerged as a strong negative predictor of AD, reaffirming its potential role as a biomarker for early detection. It would be of interest to see whether compromised blood brain barrier due to elevated blood pressure[60-62] and reduced clearance of toxic protein aggregates due to low albumin levels[63-65] contribute additively to dementia risk. There may be however and independent correlation between serum albumin and hypertension, with a study showing that low albumin levels predict hypertension[66]. Supporting this, out of all the blood borne markers we have data for, serum albumin level is the most significant negative correlator of SBP level (logODDs -0.20 Z -37.93, controlling for age and sex). This motivates further investigation of dementia incidence in people with hypoalbuminemia.

In terms of medication prescriptions, our analysis dovetails with the biometric data, showing a relatively high prescription of anti-hypertensives in the cohort going on to develop AD. As such, the drug associations reflect the risk associated with hypertension and not with taking the drug. Of the drugs showing a negative association with AD, salbutamol has been shown to be protective in PD in a relatively large epidemiological study[17] and an animal model of the disease[13], but the direct causal link has been questioned with a study claiming that the association is confounded by the relatively low PD incidence in smokers[36]. In contrast, there appears to be a consensus that smoking is a dementia risk[39], and it is difficult to argue that smoking would confound the negative association of salbutamol use with AD incidence. However, we see a negative association of nicotine prescription and AD incidence and it would be of interest to include non-prescription nicotine use in the analysis to see whether the salbutamol effect is robust. Other drugs with reported beneficial effects in dementia are two classes of T2D medications, the insulin modulating GLP-1 agonists and the glucose lowering SGLT2 inhibitors. These results are particularly interesting given the increased dementia incidence in diabetics[67]. The SGLT2 inhibitors have only been licenced relatively recently and we thus did not have data to power an analysis 10 years prior to diagnosis of AD and it will be of interest to return to the analysis once more long-term use data becomes available. The GLP-1 agonists have a longer track record as T2D medications but perhaps of greater interest is the recent licencing of the GLP-1 agonist semaglutide as a weight loss drug[68]. The subsequent larger cohort of users will facilitate a more robust association analysis. The strongest negative associations with AD incidence in AD were with postmenopausal hormonal prescriptions. The protective effects of estrogen has been a long established[54, 55], however the subsequent clinical trials proved to be disappointing[56, 57]. One criticism of the trial is that it was conducted with older women and perhaps therefore less relevant to investigating a protective effect [58]. Apart from the reported neuroprotective effects of sumatriptan in an animal stroke model[69], as far as we know the triptan class of migraine medications have not previously been reported in connection with neurodegenerative conditions. Our analysis points to the negative association of triptan prescription with AD incidence as being condition driven, as we observe a lower AD incidence in the migraine population. Further, when the analysis is restricted to those with a migraine diagnosis there is no longer a negative association of the drugs with incidence of AD. This observation highlights the importance of the inclusion of concurrent observational data in drug repurposing strategies based on prescription data.

Overall, these results underscore the importance of a multifaceted approach in understanding and addressing intervention in AD. By integrating observational data and medication histories, we can enhance our ability to predict and potentially mitigate AD risk through tailored interventions. Future research should continue to explore these associations in larger and more diverse populations, considering the potential for drug repurposing and the development of targeted preventive strategies.

## **Study limitations**

As with most retrospective studies, it is problematic to make conclusions as to causality based on correlations. For example, as shown here, the seemingly protective effects of anti-migraine medication are confounded by the lower incidence of AD in the migraine cohort. Which in turn may be due to the differential biometrics in the migraine cohort. In contrast to the analysis of biometrics and blood borne factors, where one is comparing numerical measures, the analysis of medication incidence is complicated by being categorical, where a null assignment for a given medication may be due to the lack of data. The present study aimed to circumvent this problem by filtering the cohort to ensure a degree of observation and prescription matching.

## Acknowledgements

The author would like to thank Dr Alexadru Dregan for extracting the data from CPRD and helping with technical issues, and Professor Patrick Doherty for reading the paper and providing helpful

suggestions. This study is based in part on data from the Clinical Practice Research Datalink obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. The data is provided by patients and collected by the NHS as part of their care and support. The interpretation and conclusions contained in this study are those of the author alone.

## Ethical approval

The CPRD group obtained ethical approval from a National Research Ethics Service Committee for all purely observational research using anonymised CPRD data, as in the present study. The study protocol has been approved by the Independent Scientific Advisory Committee for Medicines and Healthcare Products Regulatory Agency, Ref: 14\_111.

# **Conflict of interest statement**

The author declares that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

# References

- 1. Jaffe S: Medicare covers new Alzheimer's drug, but there is a catch. *Lancet* 2022, **399**(10335):1585.
- 2. The L: Lecanemab for Alzheimer's disease: tempering hype and hope. *Lancet* 2022, **400**(10367):1899.
- 3. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S *et al*: Lecanemab in Early Alzheimer's Disease. *N Engl J Med* 2023, **388**(1):9-21.
- 4. Mullard A: **FDA** approves second anti-amyloid antibody for Alzheimer disease. *Nat Rev Drug Discov* 2023, **22**(2):89.
- 5. Laura Joszt M: Biogen Abandons Aducanumab, Pivots Focus to Lecanemab for Alzheimer Disease. *The American Journal of Managed Care* 2024.
- 6. Xu W, Tan L, Wang HF, Jiang T, Tan MS, Tan L, Zhao QF, Li JQ, Wang J, Yu JT: **Meta-analysis** of modifiable risk factors for Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 2015, **86**(12):1299-1306.
- 7. Karch CM, Goate AM: Alzheimer's disease risk genes and mechanisms of disease pathogenesis. *Biol Psychiatry* 2015, **77**(1):43-51.
- 8. Korczyn AD, Grinberg LT: Is Alzheimer disease a disease? Nat Rev Neurol 2024, **20**(4):245-251.
- Di Marco LY, Marzo A, Munoz-Ruiz M, Ikram MA, Kivipelto M, Ruefenacht D, Venneri A, Soininen H, Wanke I, Ventikos YA *et al*: Modifiable lifestyle factors in dementia: a systematic review of longitudinal observational cohort studies. *J Alzheimers Dis* 2014, 42(1):119-135.
- 10. Silva MVF, Loures CMG, Alves LCV, de Souza LC, Borges KBG, Carvalho MDG: **Alzheimer's** disease: risk factors and potentially protective measures. *J Biomed Sci* 2019, **26**(1):33.
- 11. Ballard C, Aarsland D, Cummings J, O'Brien J, Mills R, Molinuevo JL, Fladby T, Williams G, Doherty P, Corbett A *et al*: **Drug repositioning and repurposing for Alzheimer disease**. *Nat Rev Neurol* 2020, **16**(12):661-673.
- 12. Williams G, Gatt A, Clarke E, Corcoran J, Doherty P, Chambers D, Ballard C: **Drug** repurposing for Alzheimer's disease based on transcriptional profiling of human iPSC-derived cortical neurons. *Transl Psychiatry* 2019, **9**(1):220.

- 13. Fletcher EJR, Jamieson AD, Williams G, Doherty P, Duty S: **Targeted repositioning** identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats. *Sci Rep* 2019, **9**(1):8336.
- 14. Fletcher EJR, Kaminski T, Williams G, Duty S: **Drug repurposing strategies of relevance for Parkinson's disease**. *Pharmacol Res Perspect* 2021, **9**(4):e00841.
- 15. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN *et al*: **The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease**. *Science* 2006, **313**(5795):1929-1935.
- 16. Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK *et al*: **A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles**. *Cell* 2017, **171**(6):1437-1452 e1417.
- 17. Mittal S, Bjornevik K, Im DS, Flierl A, Dong X, Locascio JJ, Abo KM, Long E, Jin M, Xu B *et al*: **beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson's disease**. *Science* 2017, **357**(6354):891-898.
- 18. Thygesen JH, Tomlinson C, Hollings S, Mizani MA, Handy A, Akbari A, Banerjee A, Cooper J, Lai AG, Li K *et al*: **COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records**. *Lancet Digit Health* 2022, **4**(7):e542-e557.
- Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L: Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015, 44(3):827-836.
- 20. Tate AR, Beloff N, Al-Radwan B, Wickson J, Puri S, Williams T, Van Staa T, Bleach A: Exploiting the potential of large databases of electronic health records for research using rapid search algorithms and an intuitive query interface. J Am Med Inform Assoc 2014, **21**(2):292-298.
- 21. Huang J, Su B, Karhunen V, Gill D, Zuber V, Ahola-Olli A, Palaniswamy S, Auvinen J, Herzig KH, Keinanen-Kiukaanniemi S *et al*: Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease: An Observational Analysis and Mendelian Randomization. *Neurology* 2023, **100**(6):e568-e581.
- 22. Zheng B, Su B, Udeh-Momoh C, Price G, Tzoulaki I, Vamos EP, Majeed A, Riboli E, Ahmadi-Abhari S, Middleton LT: Associations of Cardiovascular and Non-Cardiovascular Comorbidities with Dementia Risk in Patients with Diabetes: Results from a Large UK Cohort Study. J Prev Alzheimers Dis 2022, 9(1):86-91.
- 23. Imfeld P, Bodmer M, Jick SS, Meier CR: **Benzodiazepine Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis**. *Drug Saf* 2015, **38**(10):909-919.
- 24. Mitchell A, Snowball J, Welsh TJ, Watson MC, McGrogan A: **Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study**. *BMC Med* 2021, **19**(1):189.
- 25. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M *et al*: **UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age**. *PLoS Med* 2015, **12**(3):e1001779.
- 26. Liaw A WM: Classification and Regression by randomForest. *R news* 2002, 2(3):18-22.
- 27. Carey A, Fossati S: Hypertension and hyperhomocysteinemia as modifiable risk factors for Alzheimer's disease and dementia: New evidence, potential therapeutic strategies, and biomarkers. *Alzheimers Dement* 2023, **19**(2):671-695.
- 28. Burke GL, Hughes TM: Arterial Changes Connecting Hypertension to Alzheimer's Disease and Related Dementias. *JACC Cardiovasc Imaging* 2021, **14**(1):186-188.

- Lennon MJ, Makkar SR, Crawford JD, Sachdev PS: Midlife Hypertension and Alzheimer's Disease: A Systematic Review and Meta-Analysis. J Alzheimers Dis 2019, 71(1):307-316.
- 30. Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, Holtta M, Rosen C, Olsson C, Strobel G *et al*: **CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis**. *Lancet Neurol* 2016, **15**(7):673-684.
- 31. Altuna-Azkargorta M, Mendioroz-Iriarte M: **Blood biomarkers in Alzheimer's disease**. *Neurologia (Engl Ed)* 2021, **36**(9):704-710.
- 32. Tan CC, Yu JT, Tan L: **Biomarkers for preclinical Alzheimer's disease**. *J Alzheimers Dis* 2014, **42**(4):1051-1069.
- 33. Arslan B, Zetterberg H, Ashton NJ: **Blood-based biomarkers in Alzheimer's disease moving towards a new era of diagnostics**. *Clin Chem Lab Med* 2024, **62**(6):1063-1069.
- 34. Kim JW, Byun MS, Lee JH, Yi D, Jeon SY, Sohn BK, Lee JY, Shin SA, Kim YK, Kang KM *et al*:
   Serum albumin and beta-amyloid deposition in the human brain. *Neurology* 2020, 95(7):e815-e826.
- 35. Barthelemy NR, Salvado G, Schindler SE, He Y, Janelidze S, Collij LE, Saef B, Henson RL, Chen CD, Gordon BA *et al*: **Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests**. *Nat Med* 2024, **30**(4):1085-1095.
- 36. Searles Nielsen S, Gross A, Camacho-Soto A, Willis AW, Racette BA: **beta2**adrenoreceptor medications and risk of Parkinson disease. *Ann Neurol* 2018, **84**(5):683-693.
- 37. Durazzo TC, Mattsson N, Weiner MW, Alzheimer's Disease Neuroimaging I: **Smoking and increased Alzheimer's disease risk: a review of potential mechanisms**. *Alzheimers Dement* 2014, **10**(3 Suppl):S122-145.
- 38. Choi D, Choi S, Park SM: Effect of smoking cessation on the risk of dementia: a longitudinal study. *Ann Clin Transl Neurol* 2018, **5**(10):1192-1199.
- 39. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J *et al*: **Dementia prevention, intervention, and care**. *Lancet* 2017, **390**(10113):2673-2734.
- 40. Nop O, Senft Miller A, Culver H, Makarewicz J, Dumas JA: **Nicotine and Cognition in Cognitively Normal Older Adults**. *Front Aging Neurosci* 2021, **13**:640674.
- 41. Picciotto MR, Zoli M: Nicotinic receptors in aging and dementia. J Neurobiol 2002, 53(4):641-655.
- 42. Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, Lawrence R, McFarlane B, Tadros G, Ridha BH *et al*: **Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)**. *Trials* 2019, **20**(1):191.
- 43. Zhou B, Zissimopoulos J, Nadeem H, Crane MA, Goldman D, Romley JA: **Association between exenatide use and incidence of Alzheimer's disease**. *Alzheimers Dement (N Y)* 2021, **7**(1):e12139.
- 44. Mahase E: **NICE recommends weight loss drug semaglutide for obese adults**. *BMJ* 2022, **376**:o340.
- 45. Singh G, Krauthamer M, Bjalme-Evans M: **Wegovy (semaglutide): a new weight loss** drug for chronic weight management. *J Investig Med* 2022, **70**(1):5-13.
- 46. Tang H, Shao H, Shaaban CE, Yang K, Brown J, Anton S, Wu Y, Bress A, Donahoo WT, DeKosky ST *et al*: **Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies**. *J Am Geriatr Soc* 2023, **71**(7):2096-2106.

- 47. Hayden MR: **Type 2 Diabetes Mellitus Increases The Risk of Late-Onset Alzheimer's Disease: Ultrastructural Remodeling of the Neurovascular Unit and Diabetic Gliopathy**. *Brain Sci* 2019, **9**(10).
- 48. Pugazhenthi S, Qin L, Reddy PH: **Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease**. *Biochim Biophys Acta Mol Basis Dis* 2017, **1863**(5):1037-1045.
- 49. Diniz Pereira J, Gomes Fraga V, Morais Santos AL, Carvalho MDG, Caramelli P, Braga Gomes K: Alzheimer's disease and type 2 diabetes mellitus: A systematic review of proteomic studies. *J Neurochem* 2021, **156**(6):753-776.
- 50. Kim J, Ha WS, Park SH, Han K, Baek MS: **Association between migraine and Alzheimer's disease: a nationwide cohort study**. *Front Aging Neurosci* 2023, **15**:1196185.
- 51. Islamoska S, Hansen AM, Wang HX, Garde AH, Andersen PK, Garde E, Hansen JM, Waldemar G, Nabe-Nielsen K: Mid- to late-life migraine diagnoses and risk of dementia: a national register-based follow-up study. *J Headache Pain* 2020, **21**(1):98.
- 52. Tronvik E, Zwart JA, Hagen K, Dyb G, Holmen TL, Stovner LJ: **Association between blood** pressure measures and recurrent headache in adolescents: cross-sectional data from the HUNT-Youth study. *J Headache Pain* 2011, **12**(3):347-353.
- 53. Secil Y, Unde C, Beckmann YY, Bozkaya YT, Ozerkan F, Basoglu M: **Blood pressure** changes in migraine patients before, during and after migraine attacks. *Pain Pract* 2010, **10**(3):222-227.
- 54. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R: **Effect** of oestrogen during menopause on risk and age at onset of Alzheimer's disease. *Lancet* 1996, **348**(9025):429-432.
- 55. Paganini-Hill A, Henderson VW: Estrogen replacement therapy and risk of Alzheimer disease. *Arch Intern Med* 1996, **156**(19):2213-2217.
- 56. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, 3rd, Assaf AR, Jackson RD *et al*: **Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial**. *JAMA* 2003, **289**(20):2651-2662.
- 57. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE *et al*: **Conjugated equine estrogens and incidence of probable dementia** and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. *JAMA* 2004, **291**(24):2947-2958.
- 58. Henderson VW: Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. *Neuroscience* 2006, **138**(3):1031-1039.
- 59. Norgaard M, Horvath-Puho E, Corraini P, Sorensen HT, Henderson VW: Sleep disruption and Alzheimer's disease risk: Inferences from men with benign prostatic hyperplasia. *EClinicalMedicine* 2021, **32**:100740.
- 60. Katsi V, Marketou M, Maragkoudakis S, Didagelos M, Charalambous G, Parthenakis F, Tsioufis C, Tousoulis D: **Blood-brain barrier dysfunction: the undervalued frontier of hypertension**. *J Hum Hypertens* 2020, **34**(10):682-691.
- 61. Kuwahara H, Nishida Y, Yokota T: **[Blood-brain barrier and Alzheimer's disease]**. *Brain Nerve* 2013, **65**(2):145-151.
- 62. Biancardi VC, Stern JE: **Compromised blood-brain barrier permeability: novel mechanism by which circulating angiotensin II signals to sympathoexcitatory centres during hypertension**. *J Physiol* 2016, **594**(6):1591-1600.
- 63. Milojevic J, Costa M, Ortiz AM, Jorquera JI, Melacini G: In vitro amyloid-beta binding and inhibition of amyloid-beta self-association by therapeutic albumin. *J Alzheimers Dis* 2014, **38**(4):753-765.

- 64. Costa M, Ortiz AM, Jorquera JI: **Therapeutic albumin binding to remove amyloid-beta**. *J Alzheimers Dis* 2012, **29**(1):159-170.
- 65. Prajapati KD, Sharma SS, Roy N: **Current perspectives on potential role of albumin in neuroprotection**. *Rev Neurosci* 2011, **22**(3):355-363.
- 66. Oda E: Decreased serum albumin predicts hypertension in a Japanese health screening population. *Intern Med* 2014, **53**(7):655-660.
- 67. Biessels GJ, Despa F: Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. *Nat Rev Endocrinol* 2018, **14**(10):591-604.
- 68. Lexchin J, Mintzes B: **Semaglutide: a new drug for the treatment of obesity**. *Drug Ther Bull* 2023, **61**(12):182-188.
- 69. Shayan M, Eslami F, Amanlou A, Solaimanian S, Rahimi N, Rashidian A, Ejtemaei-Mehr S, Ghasemi M, Dehpour AR: Neuroprotective effects of Lasmiditan and Sumatriptan in an experimental model of post-stroke seizure in mice: Higher effects with concurrent opioid receptors or K(ATP) channels inhibitors. *Toxicol Appl Pharmacol* 2022, **454**:116254.

# **Supplementary Data**

Table S1. The SNOMED codes and descriptions for AD assignment in the case cohort. First ever diagnosis of AD was between 1/1/2012 and 31/12/2022 and this was defined as the index date for control cohort matching.

Original Read Code	Term	Snomed CT Concept Id	Snomed CT Description Id
F110	Alzheimer's disease	26929004	45046017
Eu00	[X]Dementia in	[X]Dementia in 26929004	
	Alzheimer's disease		
Eu002	[X]Dementia in	26929004	45046017
	Alzheimer's dis, atypical		
	or mixed type		
Eu00z	[X]Dementia in	26929004	45046017
	Alzheimer's disease,		
	unspecified		
Fyu30	[X]Other Alzheimer's	26929004	45046017
	disease		
Eu00z-1	[X]Alzheimer's dementia	26929004	45046017
	unspec		
^ESCTAD293123	AD - Alzheimer's disease	26929004	1225144019
^ESCTAL293124	Alzheimer disease	26929004	2839267017
^ESCTAL293125	Alzheimer dementia	26929004	3424952012
Eu025	Diffuse Lewy body	80098002	132893017
	disease		
F116	Lewy body disease	80098002	132893017
^ESCTLE380262	Lewy body variant of	80098002	132894011
	Alzheimer's disease		
^ESCTLB380264	LBD - Lewy body disease	80098002	1234436013
^ESCTDE380265	Dementia of the Lewy	80098002	1234437016
	body type		
^ESCTCO380267	Cortical Lewy body	80098002	1234439018
	disease		
^ESCTFA500550	Familial Alzheimer's	230265002	345083019
	disease of early onset		

^ESCTFA500554	Familial Alzheimer's	230267005	345085014
	disease of late onset		
^ESCTFO500558	Focal Alzheimer's disease	230269008	345087018
F1100	Alzheimer's disease with early onset	416780008	2957141019
Eu000-3	[X]Alzheimer's disease type 2	416780008	2957119019
Eu000	Dementia in Alzheimer's disease with early onset	416780008	2957119019
Eu000-1	[X]Presenile dementia,Alzheimer's type	416780008	2957138011
Eu000-2	[X]Primary degen dementia, Alzheimer's type, presenile onset	416780008	2957119019
^ESCTPR689721	Primary degenerative dementia of the Alzheimer type, presenile onset	416780008	2549310013
^ESCTDE689724	Dementia of the Alzheimers type with early onset	416780008	2957133019
^ESCTPR689725	Presenile dementia, Alzheimer's type	416780008	2957138011
^ESCTDE689727	Dementia in Alzheimer's disease - type 2	416780008	2957156011
F1101	Alzheimer's disease with late onset	416975007	2957124016
Eu001-1	[X]Alzheimer's disease type 1	416975007	2957137018
Eu001	Dementia in Alzheimer's disease with late onset	416975007	2957137018
Eu001-3	[X]Primary degen dementia of Alzheimer's type, senile onset	416975007	2957137018
Eu001-2	[X]Senile dementia,Alzheimer's type	416975007	2957124016
^ESCTPR690018	Primary degenerative dementia of the Alzheimer type, senile onset	416975007	2549518019
^ESCTDE690020	Dementia of the Alzheimers type, late onset	416975007	2957123010
^ESCTSD690022	SDAT - Senile dementia, Alzheimer's type	416975007	2957134013
^ESCTDE690024	Dementia in Alzheimer's disease - type 1	416975007	2957155010
^ESCTNO783407	Non-amnestic Alzheimer disease	722600006	3332846016
^ESCTMI802420	Mixed dementia	79341000119107	2955467016
^ESCT1237064	Dementia with mixed etiology	79341000119107	3670850017

^ESCT1237065	MVAD - Mixed vascular	79341000119107	3670851018
	Alzheimer dementia		
^ESCT1237066	Dementia with mixed aetiology	79341000119107	3670852013
^ESCTDE804491	Delusions in Alzheimer's disease	141991000119109	2968442016
^ESCTDE804494	Depressed mood in Alzheimer's disease	142001000119106	2968437012
^ESCTNO500556	Non-familial Alzheimer's disease of late onset	230268000	345086010
^ESCTNO500552	Non-familial Alzheimer's disease of early onset	230266001	345084013
^ESCTAL804498	Alzheimer's disease co- occurrent with delirium	142011000119109	3311926019
^ESCTPR257573	Primary degenerative dementia of the Alzheimer type, senile onset, with delirium	4817008	9023015
^ESCTPR292993	Primary degenerative dementia of the Alzheimer type, senile onset, with depression	26852004	44934012
^ESCTEA803291	Early onset Alzheimer's disease with behavioural disturbance	105421000119105	2985868010
^ESCTEA803293	Early onset Alzheimers disease with behavioral disturbance	105421000119105	2987421013
^ESCTDE796928	Dementia of the Alzheimer type with behavioural disturbance	1581000119101	2967544019
^ESCTPR357504	Primary degenerative dementia of the Alzheimer type, senile onset, uncomplicated	66108005	109791011
^ESCTPR260327	Primary degenerative dementia of the Alzheimer type, presenile onset, uncomplicated	6475002	11739017
EMISNQDD3	[D] Dementia in Alzheimer's disease	914951000006105	914951000006114
EMISICD10 F0024	Dementia in Alzheimer's dis, atypical or mixed type, other mixed symptoms	1972341000006107	1972341000006111
EMISICD10 F0094	Dementia in Alzheimer's disease, unspecified, other mixed symptoms	1972471000006107	1972471000006111
EMISICD10 F0020	Dementia in Alzheimer's dis, atypical or mixed type, without additional symptoms	1972231000006105	1972231000006114
HNG0062	[RFC] Alzheimer's disease	905791000006104	905791000006115

EMISICD10 F0014	Dementia in Alzheimer's	1972211000006104	1972211000006115
	disease with late onset,	197221100000104	197221100000115
	other mixed symptoms		
EMISICD10 F0004	Dementia in Alzheimer's	1972141000006109	1972141000006113
	disease with early onset,	1572141000000105	15/214100000115
	other mixed symptoms		
EMISICD10   F0090	Dementia in Alzheimer's	1972371000006104	1972371000006115
'	disease, unspecified,		
	without additional		
	symptoms		
EMISICD10   F0010	Dementia in Alzheimer's	1972171000006101	1972171000006117
	disease with late onset,		
	without additional		
	symptoms		
EMISICD10 F0022	Dementia in Alzheimer's	1972291000006109	1972291000006113
	dis, atypical or mixed		
	type, other symptoms,		
	predominantly		
	hallucinatory		
EMISICD10 F0021	Dementia in Alzheimer's	1972251000006103	1972251000006119
	dis, atypical or mixed		
	type, other symptoms, predominantly		
	delusional		
EMISICD10 F0023	Dementia in Alzheimer's	1972311000006108	1972311000006112
	dis, atypical or mixed	1372311000000108	15/251100000112
	type, other symptoms,		
	predominantly		
	depressive		
EMISICD10   F0000	Dementia in Alzheimer's	1971401000006107	197140100006111
	disease with early onset,		
	without additional		
-	symptoms		
EMISICD10 F0013	Dementia in Alzheimer's	1972201000006102	1972201000006118
	disease with late onset,		
	other symptoms,		
	predominantly		
	depressive Dementia in Alzheimer's	1972451000006102	1072451000006118
EMISICD10 F0093	disease, unspecified,	1972451000000102	1972451000006118
	other symptoms,		
	predominantly		
	depressive		
EMISICD10   F0011	Dementia in Alzheimer's	1972181000006103	1972181000006119
	disease with late onset,		
	other symptoms,		
	predominantly		
	delusional		
EMISICD10 F0003	Dementia in Alzheimer's	1972131000006104	1972131000006115
	disease with early onset,		
	other symptoms,		
	predominantly		
	depressive		
EMISICD10 F0091	Dementia in Alzheimer's	1972401000006101	1972401000006117
	disease, unspecified,		
L	other symptoms,	1	

	predominantly delusional		
EMISICD10 F0012	Dementia in Alzheimer's disease with late onset, other symptoms, predominantly hallucinatory	1972191000006100	197219100006116
EMISICD10 F0001	Dementia in Alzheimer's disease with early onset, other symptoms, predominantly delusional	1971541000006105	1971541000006114
EMISICD10 F0002	Dementia in Alzheimer's disease with early onset, other symptoms, predominantly hallucinatory	1971771000006108	1971771000006112

Table S2. The SNOMED codes and descriptions for T2D assignment.

Original Read Code	Term	Snomed CT Concept Id	Snomed CT Description Id
L1809	Gestational diabetes mellitus	11687002	20191016
C1001-2	Non-insulin dependent diabetes mellitus	44054006	493773010
C10	Diabetes mellitus	73211009	121589010
C10F	Type 2 diabetes mellitus	44054006	197761014
1252	FH: Diabetes mellitus	160303001	249794016
1434	H/O: diabetes mellitus	161445009	251591016
C10F-1	Type II diabetes mellitus	44054006	493774016
C109-2	Type 2 diabetes mellitus	44054006	197761014
8CA41	Diabetes mellitus diet education	284350006	2575925018
C109	Non-insulin dependent diabetes mellitus	44054006	493773010
C108	Insulin dependent diabetes mellitus	73211009	121589010
EMISNO3	No H/O: diabetes mellitus	857361000006103	857361000006119
HNG0605	[RFC] Diabetes mellitus	908831000006102	908831000006118
C10FJ	Insulin treated Type 2 diabetes mellitus	237599002	2967820013

<b>Original Read Code</b>	Term	Snomed CT Concept Id	<b>Snomed CT Description Id</b>	
F260-1	Migraine with aura	4473006	7595017	
F260	Migraine with typical aura	230462002	345348012	
F26	Migraine	37796009	63055014	
F261-1	Migraine without aura	56097005	93294013	
F261	Common migraine	56097005	93295014	
1297	FH: Migraine	160342001	249890015	
1474	H/O: migraine	161481007	251645017	
F261z	Common migraine NOS	56097005	93295014	
F262	Migraine variants	193030005	297337016	
F262z	Migraine variant NOS	193030005	297337016	
F26z	Migraine NOS	37796009	63055014	
8B6N	Migraine prophylaxis	408381007	2159945013	
14740	History of migraine with aura	608837004	2958210010	
EMISNQH/12	H/O: migraine with aura	1763401000006105	1763401000006114	
EMISNQH/13	H/O: migraine without aura	1763411000006108	1763411000006112	
^ESCTCL257016	Classical migraine	4473006	7596016	
^ESCTHI454016	History of migraine	161481007	2986612014	
^ESCTCO476993	Complex migraine	193039006	2966546010	
^ESCTMI500829	Migraine aura without headache	230465000	345351017	
^ESCTRE701607	Refractory migraine	423894005	2644986016	
^ESCTMI730629	Migraine variant with headache	445322004	2872940010	
^ESCTMI752039	Migraine with persistent visual aura	699314009	2983774015	
^ESCTCH803879	Chronic intractable migraine without aura	124171000119105	2967600014	
^ESCT1234532	Chronic migraine	427419006	3638229012	

Table S4. The blood borne measures and biometric data together with their averages and standard deviations. Data for these variables was collected for the case and control cohorts and only values falling within two standard deviations of the mean were included in the analysis.

Measure	AVE	SD
Neutrophil count	4.581796	4.416166
Basophil count	0.04585	0.308122
Platelet count	267.4525	80.80724
Monocyte count	0.567595	1.788406

Eosinophil count	0.211243	0.881311
Lymphocyte count	2.168272	4.066914
Serum C reactive protein level	10.40646	24.78166
Nucleated red blood cell count	0.027757	0.463456
Serum bilirubin level	309.9447	305.2885
Corrected serum calcium level	2.383231	3.273162
Serum high density lipoprotein cholesterol level	1.457952	1.016703
Serum low density lipoprotein cholesterol level	2.885637	1.500549
Plasma fasting glucose level	5.666369	10.16407
Serum albumin level	42.00783	4.337708
Serum sodium level	139.6322	4.714234
	26.46625	26.42589
Serum aspartate aminotransferase level Serum creatinine level		
	83.31377	35.19167
Serum urate level	249.8492	190.4155
Serum urea level	5.977894	3.183229
Serum luteinising hormone level	13.79889	16.40006
Plasma urea level	5.744658	3.030966
Serum thyroid stimulating hormone level	2.540394	6.414843
Plasma thyroid stimulating hormone level	2.485047	7.091601
HbA1c level	7.257907	4.981173
Serum free triiodothyronine level	5.669793	3.804148
Serum free T4 level	15.01162	5.020864
Serum total bilirubin level	10.06324	8.484136
Serum gamma-glutamyl transferase level	54.16035	103.3814
Plasma gamma-glutamyl transferase level	50.21046	86.74896
Plasma creatinine level	83.43387	35.93568
Plasma total bilirubin level	11.00833	10.4315
Plasma high density lipoprotein cholesterol level	1.397647	0.419721
Urine microalbumin level	32.8716	109.1479
Plasma albumin level	40.66991	4.225833
Plasma total cholesterol level	4.952289	1.225716
Plasma sodium level	139.2439	3.313736
Plasma alanine aminotransferase level	26.62394	35.96136
Plasma alkaline phosphatase level	116.6087	84.45989
Plasma calcium level	2.375753	0.122061
Plasma potassium level	4.138521	0.950778
Calculated low density lipoprotein cholesterol level	2.833689	1.182399
Serum creatine kinase level	128.2204	126.8469
Serum total cholesterol level	5.028981	2.580017
Urine albumin level	35.93196	118.2024
Urine creatinine level	13.64487	90.30944
Thyroid stimulating hormone level	2.911864	11.787
Total alkaline phosphatase level	84.17497	50.05719
Total white cell count	7.417013	8.405416

ALT/SGPT serum level	28.48148	33.43329
Blood glucose level	6.572861	6.822651
Haemoglobin A1c level	7.717305	7.205028
Serum glucose level	5.765725	3.269726
Serum follicle stimulating hormone level	21.15659	29.55843
Plasma glucose level	5.932626	10.43315
Serum ferritin level	96.63587	142.6043
Serum folate level	8.56991	6.817203
Serum globulin level	28.67102	4.864038
Serum inorganic phosphate level	1.124378	1.289073
Serum iron level	14.83141	10.99456
Serum potassium level	4.428088	1.214448
Serum testosterone level	6.603195	8.670323
Serum transferrin level	3.252408	21.23239
Serum triglycerides level	1.665449	1.331858
Serum vitamin B12 level	403.5655	231.3958
Serum alkaline phosphatase level	87.00863	53.79808
Serum bicarbonate level	26.39662	4.142428
Serum calcium level	2.363842	1.642945
Serum chloride level	101.2795	9.543153
Serum cholesterol level	5.047981	2.307462
Red blood cell count	4.512244	4.189216
Prostate-specific antigen level	5.557065	36.24308
Serum alanine aminotransferase level	26.27311	33.63325
Non high density lipoprotein cholesterol level	3.469771	1.146355
Haemoglobin A1c level	46.1461	15.69581
Calcium adjusted level	2.381319	1.666903
Serum prostate specific antigen level	6.247608	41.4478
Serum non high density lipoprotein cholesterol level	3.427815	1.136847
Serum total 25-hydroxy vitamin D level	55.12612	28.85768
Systolic arterial pressure	133.3399	20.99563
Diastolic arterial pressure	78.29111	12.19942
weight	73.92255	26.27838
height	159.714	32.51027